Kura Oncology, Inc. (NASDAQ: KURA) is a Healthcare company (Biotechnology) with a market capitalization of $688M. The Maz Rating grades it against the other companies in its sector.
Kura Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.49, Kura Oncology, Inc. trades at 8.7x sales and 37.4x book value. Over the last twelve months it generated about $79M of revenue and a net loss of $304M. It runs a gross margin of 98.4%, an operating margin of -394.3% and a net margin of -369.3%. It shows return on equity of -336.2%, return on invested capital of -73.0% and a free cash flow yield of -13.0%. On the balance sheet: a debt-to-equity ratio of 1.44 and a current ratio of 3.60. Over the past 52 weeks the share price ranged from $6.75 to $13.90, with a beta of 0.38.
Kura Oncology, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 15 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.